Hiba Therapeutics is developing a cancer-targeted T cell engager platform that specifically engages tumor-infiltrated T cells using their TROIKA platform, which aims to safely bridge TIL efficacy with the scalability of biologics for the effective elimination of solid cancers
Hiba Therapeutics is developing a cancer-targeted T cell engager platform that specifically engages tumor-infiltrated T cells using their TROIKA platform, which aims to safely bridge TIL efficacy with the scalability of biologics for the effective elimination of solid cancers.